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Abstract
Background: Previous evidence have demonstrated that p21-activated kinase PAK4 was correlated with breast
cancer. The aim of this paper is to study the expression and interaction of p21-activated kinase (pAK)-4 and P54
protein in breast cancer.
Methods: A total of 80 patients were enrolled in our study (breast fibroma n = 20, breast noninvasive cancer n = 20,
early breast invasive cancer n = 20, and advanced breast invasive cancer). The expression of PAK4 was detected by
immunohistochemical S-P method, and the relationship between them and the different pathological characteristics
were compared. The subcellular localization of P54 and PAK4 in vitro was observed by immunofluorescence assay.
Results: The expression of both PAK4 and P54 in breast cancer was much higher than that in breast fibroma.
Meanwhile, we found that both PAK4 and P54 increased gradually as breast cancer progressed (advanced invasive >
early invasive > noninvasive). The positive staining of P54 were mainly located in the cytoplasm, especially around the
nucleus. There was no significant stained region in the cell matrix. The P54 localization in the cytoplasm was verified by
confocal experiment, and the PAK4 was co-localized.
Conclusions: PAK4 and P54 proteins may be used as molecular markers for diagnosis and treatment of breast cancer.
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Background
Breast cancer ranks the first among women malignant
tumors, accounting for 7 to 10 % of the whole body
cancer. Peripheral blood tumor marker detection is an
important measure for early diagnosis of breast cancer.
CA125, CEA, and TPS are the present common serum
tumor markers. HER-2/Neu, estrogen receptor (ER),
progesterone receptor (PR), epidermal growth factor
receptor (EGFR), vascular endothelial growth factor
receptor (VEGFR), and vascular endothelial growth fac-
tor (VEGF) are detected by pathological specimens. The
positive rate and positive predictive value are not that
satisfactory and are often used as reference index for
clinical diagnosis and treatment. Along with advance-
ment of scientific research, the pathways for phosphoryl-
ation/de-phosphorylation of proteins are found to be
important for signal transduction, and their balance has
a crucial role in the cell’s normal signal transduction and
tumor occurrence or development. There have been
some studies that p21-activated kinase (pAK)-4 has a high
expression in breast cancer and ovarian cancer [1–3]. The
purpose of our study was to explore the expression of
PAK4 and P54 in breast cancer and the correlation of
these proteins with pathological stages of breast cancer.
Methods
Clinical specimens
A total of 80 patients from April 2013 to April 2015 were
enrolled in our study (breast fibroma n = 20, breast nonin-
vasive cancer n = 20, early breast invasive cancer n = 20,
and advanced breast invasive cancer).
The ages of patients with breast fibroma ranged from
30 to 72 years with a mean value of 44.5 ± 16.3 years.
And the ages of patients with breast noninvasive cancer
ranged from 29 to 66 years with a mean value of 42.5 ±
10.3 years. Among them, there were five ER-positive
cases, four PR-positive cases, and three double-positive
cases. The ages of patients with early breast invasive
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cancer ranged from 32 to 73 years with a mean value of
45.6 ± 14.2 years. Among them, there were four ER-
positive cases, five PR-positive cases, and five double-
positive cases. The ages of patients with advanced breast
invasive cancer ranged from 46 to 77 years with a mean
value of 52.3 ± 16.7 years. Among them, there were six
ER-positive cases, four PR-positive cases, and four
double-positive cases.
All the patients were treated for the first time without
drug treatment, surgical resection, chemotherapy his-
tory, severe heart, liver, kidney, other organ dysfunction,
or other malignant tumors, etc. For the study, we
obtained the consent of the patients and their families,
and this study was approved by the ethics committee of
our hospital. For the same tissue, specimens were
obtained from three different loci and completed by the
same experienced expert, and the specimens were all
fixed by 10 % formalin and embedded in paraffin with 4-
μm continuous slicing.
Immunohistochemistry S-P method
Main reagents and equipment
For this study, we used the following: rabbit IgG
(Nanjing Kaiji Company) and peroxidase-labeled goat
anti-rabbit IgG (Shenzhen Jinmei Biological Co., Ltd.),
antibody dilutions (Wuhan Boshide Biotechnology Com-
pany), constitutive rafter acid salt buffer liquid powder
(Nanjing Kaiji Company), and neutral gum (Shanghai
Specimen Model Factory). Paraffin sections made from a
tissue-slicing machine (Leica, Germany) were dewaxed
in water; 3 % H2O2 was incubated at room temperature
for 5 ~ 10 min, to eliminate endogenous peroxidase ac-
tivity. The S-P immunohistochemical reagent kit was
provided by Fujian Maixin Biotechnology Company.
Procedure
The sections on the slides were rinsed three times in
water and PBS, to keep the antigen intact (Shanghai
Fengxian Shenxin Chemical Factory). After rinsing with
PBS three times, goat serum (Guangzhou Jietewei Com-
pany) was flooded on sections for 20 min at room
temperature. Subsequently, the first 50 μl of rabbit anti-
human PAK4 polyclonal antibody (l: 200 dilution)
(Germany BioGenes GmbH) was added to the sections
and incubated at 37 °C for 1 ~ 2 h, followed by incuba-
tion at 4 °C overnight. The next day, the slides were
washed with PBS at 37 °C for 45 min, rinsed three times
with PBS. Next, biotin-labeled sheep anti-rabbit IgG
antibody was added to sections at 37 °C and incubated
for 10 to 30 min. It was followed by three times PBS
washing, then HRP streptavidin solution was added and
the slides were incubated at 37 °C for 10 to 30 min. The
slides were rinsed with PBS three times, and DAB
solution (Guangzhou Jietewei Company) was added for
5 ~ 10 min, followed by PBS wash for 10 min. Finally,
the sections were counterstained with hematoxylin
staining for 2 min, hydrochloric acid alcohol was differ-
entiated, and ammonia turned back to blue. In the next
step, the sections were washed with tap water for 10 ~
15 min, dehydrated and transparent, and mounted for
microscopic examination (OLYMPUS BX-4O optical
microscope, Olympus, Japan).
Scoring for stained sections
For interpretation of results, the Standard of Campo was
followed (3). No color was given 0 points, weak color 1
point, moderate color 2 points, and strong color 3
points. Stained cells accounted for the total number of
cells were less than 5 % for 0 points, 5 ~ 25 % for 1
point, 26 ~ 50 % for 2 points, and more than 51 % for 3
points. Finally, the results were determined by the total
score of the percentage of positive cells and the staining in-
tensity score: 0 points for negative, 1 to 2 points for weak
positive, 3 to 4 points for medium positive, and more than
5 points for the strong positive. The results of the test were
double blind-determined by two pathologists based on the
same criteria. The different results were double blind-
determined by another pathologist, and the mean value of
the three persons was included in the statistics.
Immunofluorescence
The cells were placed on a 12-hole cell culture plate,
until the cells adhere to start expressing P54 and PAK4
protein plasmid; a double free DMEM was added to
incubate for 4 h, which was later replaced with a DMEM
culture medium, and the cells were cultured for 24 h, to
guarantee outward plasmid normal protein expression.
After 24 h, the culture medium was discarded and
washed three times with PBS. The PBS was discarded,
and the cells were fixed with 700 μl of 4 % paraform for
10 min. After three times washing with PBS, 0.1 %
Triton-X-100 was added to permeabilize the cell at room
Table 1 Expression of PAK4 in different breast tissues
Group No. of cases Negative Weakly positive Moderately positive Strong positive Kruskal-Wallis p value
Normal tissue 20 15 5 0 0 15.623 <0.001
Fibroma 20 10 7 3 0
Metastatic tumor tissue 20 6 8 4 2
Breast cancer 20 1 2 8 9
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temperature for 10 min. Next, again the slides were
rinsed with PBS three times, followed by addition of 1 %
sheep serum at room temperature for 1 h. Subsequently,
the slides were incubated with the anti-PAK4 (1:2000)
and anti-myc (1:2000) antibody at room temperature for
1 h and washed with PBS three times. Subsequently,
Alexa-546 red mark goat anti-mouse antibody (1:5000)
was added to incubate for l h in dark, followed by wash-
ing with PBS three times. Topro-3 nuclear staining was
performed for 30 min and later washed with PBS three
times. Finally, 50 % glycerol was added to the slides for
mounting, to observe the subcellular localization of
proteins in confocal laser scanning microscopy.
Statistical analysis
SPSS20.0 software (SPSS Chicago, Ill) was used for the
statistical analysis. All quantitative data were expressed
as mean ± standard deviation. Comparison between
groups was done using one-way ANOVA test followed
by a post hoc test (LSD). Percentage (%) was used to
express the enumeration data, and a chi-squared test
was used for data analysis. The nonparametric total
rank of independent samples of grade data was used
to test. p values <0.05 were considered statistically
significant
Results
Expression of PAK4 protein in different breast tissues
Expression of PAK4 in breast cancer was much higher
than that in breast fibroma, and we found that PAK4
increased gradually as breast cancer progressed (ad-
vanced invasive > early invasive > noninvasive). The
positive products were mainly located in the cytoplasm,
especially obvious around the nucleus, and there was no
Table 2 Expression of PAK4 in different pathological types
Pathological type No. of cases Negative Weakly positive Moderately positive Strong positive Kruskal-Wallis p value
Noninvasive carcinoma 4 1 1 1 1 12.432 <0.001
Early invasive carcinoma 6 0 1 3 2
Advanced invasive carcinoma 10 0 0 4 6
Fig. 1 Expression of PAK4 protein in different breast tissues detected by immunohistochemistry. a Normal tissue. b Fibroma. c Metastatic tumor
tissue. d Breast cancer
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significant dyeing in the cell matrix (p < 0.05) (Table 1,
Fig. 1).
Expression of PAK4 protein in different pathological types
Expression of P54 in breast cancer was much higher
than that in breast fibroma, and we found that P54 in-
creased gradually as breast cancer progressed (advanced
invasive > early invasive > noninvasive). The differences
were all statistically significant (p < 0.05) (Table 2).
Cellular localization of P54 and PAK4 proteins
P54 localization in the cytoplasm was verified by con-
focal experiment, and the PAK4 was co-localized as
shown in Figs. 2 and 3. Expression of both PAK4 and
P54 in breast cancer was much higher than that in
breast fibroma and increased gradually as breast cancer
progressed (advanced invasive 32.6 ± 8.2 % > early inva-
sive 12.4 ± 3.5 % > noninvasive 2.0 ± 0.5 % > breast
fibroma 0.2 ± 0.1 %; F = 20.325, p < 0.001).
Discussion
PAK, P21 small GTP-activated kinase, is a serine/threo-
nine protein kinase family. The molecular weight of
21kD, small GTP enzyme of Rho family, Cdc42, and Racl
are the upstream molecules of PAKS, in the molecular
structure; the end of N PAK is the regulation region of
the kinase; the end of C is the substrate binding region
with kinase activity [4]. PAK4 is a member of the PAK
family, which is closely related to human tumor. It plays
an important role in the repair of the cytoskeleton, the
life of the normal cells, the positive regulation of some
normal physiological metabolism, etc. [5–9]. In our
study, expression of PAK4 in breast cancer was much
higher than that in breast fibroma and increased
gradually as breast cancer progressed (advanced invasive
> early invasive > noninvasive). The positive products
were mainly located in the cytoplasm, around the nu-
cleus, as there was no significant staining in the cell
matrix. The positive rate of PAK4 expression in noninva-
sive carcinoma, early invasive carcinoma, and advanced
invasive carcinoma increased gradually, and the differ-
ences were all statistically significant. It shows that
PAK4 may be used as a sensitive indicator and has im-
portant significance in judging the malignant degree and
pathological types of breast cancer.
There is some research by constructing PAK4
eukaryotic expression vector and PAK4 ShRNA eukaryotic
expression vector, transfecting breast cancer MDA-MB-
231 cells, which showed that after up-regulation of PAK4
expression in breast cancer cells, it can significantly pro-
mote breast cancer cell proliferation; inhibit apoptosis;
increase cell adhesion, movement, invasion, tumorigen-
esis, and other biological activity; and vice versa [10]. The
normal mammary gland epithelium has active cell prolif-
eration and cell apoptosis; in normal circumstances, there
is a dynamic balance between cell proliferation and cell
apoptosis, which is the main mechanism of breast muco-
sal removal of damaged cells [11, 12]. PAKs family plays
an important role in the process of cell repair. Studies
have shown that PAK4 is regulated by growth factors [13].
Fig. 2 Subcellular localization of GFP-P54 protein. a Green GFP-p54. b Blue Topro3. c Merged
Fig. 3 Cellular co-localization of GFP-P54 protein and PAK4 protein. a Green GFP-p54. b Red His-PAK4. c Blue Topro3. d Merged
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P54 protein is a kind of neuron-specific protein, and it is
an effective microtubule instability factor and membrane-
associated protein. P54 protein has a certain relationship
with tumor, and P54 provides a new basis for the further
improvement of PAK4 tumor signaling pathway [14, 15].
P54 as a member of the family has a structure of three
functional regions: the membrane-binding region of the N
end, the central regulatory region, and the coiled coil
region of the C end. In the center of regulation of phos-
phorylation sites, there are phosphorylation sites of MAP
and PKA kinase, and these phosphorylation sites can
regulate microtubule depolymerization [16, 17].
Our study showed that the expression of P54 in breast
cancer was much higher than that in breast fibroma and
increased gradually as breast cancer progressed (ad-
vanced invasive > early invasive > noninvasive). We also
found that P54 is located in the cytoplasm with PAK4
co-located. Two hybrid experiments have been shown
through yeast, screen-interacting protein P54 and PAK4,
and they were transferred to the AH109 yeast strain for
yeast verification [18]. The results showed that both
could interact; GST pull-down assay results further
confirmed the interaction in vitro, and immune precipi-
tation experiment verified the interaction in vivo. In sum-
mary, AK4 and P54 proteins may be used as molecular
markers for diagnosis and treatment of breast cancer.
Conclusions
PAK4 expression in breast cancer is adjacent normal tis-
sues, breast fibroma, and breast cancer metastasis tis-
sues, and breast cancer increased gradually. The positive
staining was mainly located in the cytoplasm, especially
more obvious around the nucleus. Besides, the positive
rate of PAK4 expression in noninvasive carcinoma, early
invasive carcinoma, and advanced invasive carcinoma
also increased gradually. The P54 localization in the
cytoplasm and the PAK4 was co-localized, so that PAK4
and P54 proteins may be used as molecular markers for
diagnosis and treatment of breast cancer.
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